Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Myelofibrosis is stable year-over-year with ... The study, which will have a primary implant of high-score 75 is expected to begin in the first half of 2025 and could represent a new treatment ...

Skin turgor and elasticity were poor ... polycythemia rubra vera and agnogenic myeloid metaplasia with myelofibrosis. Thrombocytosis secondary to splenectomy and acute hemorrhage or, rarely ...

Opens in a new tab or window About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to ...

Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

What do you think is worth looking out for in the future for myelofibrosis? I thought we could focus first on non–drug-related research that is needed to move the field forward. What do you ...

Promising Improvement in Abs-TSS and SVR35 from Phase 1 Trial of Selinexor in Combination with Ruxolitinib Adds Confidence in Phase 3 SENTRY Trial Proactively Increasing Total Sample Size of the ...

Karyopharm intends to enroll approximately 350 JAKi naïve patients with myelofibrosis in this Phase 3 trial; patients are randomized 2-to-1 to the selinexor arm. The co-primary endpoints will be ...

"There remains a tremendous unmet need in myelofibrosis, as less than half ... 3 SENTRY trial increases based on the change in the co-primary endpoint to Abs-TSS, the increased sample size and ...

Inrebic showed superior spleen volume reduction and symptom response compared to BAT in myelofibrosis patients previously treated with Jakafi. The FREEDOM2 trial involved 134 patients treated with ...